ONCO Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2023Q4

-714.000

+31.25%

Estimates Revision

Stock Price

Go Down

-58.74%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Onconetix Inc (ONCO.O) is -0.00, compared to its 5-year average forward P/E of -2.37. For a more detailed relative valuation and DCF analysis to assess Onconetix Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.37

Current PE

-0.00

Overvalued PE

6.01

Undervalued PE

-10.74

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.41

Current EV/EBITDA

-0.06

Overvalued EV/EBITDA

7.09

Undervalued EV/EBITDA

-11.90

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

10.44

Current PS

0.00

Overvalued PS

50.69

Undervalued PS

-29.81

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ONCO News & Events

Events Timeline

No data

News

3.5

2025-12-30Yahoo Finance

Authparency.ai Wins First Prize at Southlake Innovation Cup for Solving Healthcare Authorization Issues

8.5

2025-09-26Newsfilter

Onconetix Secures $12.9 Million in Financing via Series D Preferred Stock and Warrants, Ends Merger Agreement with Ocuvex, Inc., and Settles $8.8 Million Debt with Veru, Inc.

8.5

2025-09-26Newsfilter

Joint Announcement: Onconetix and Ocuvex Declare End of Merger Agreement

People Also Watch

Frequently Asked Questions

What is Onconetix Inc (ONCO) stock price today?

The current price of ONCO is 1.7 USD — it has decreased -1.16 % in the last trading day.

What is Onconetix Inc (ONCO)'s business?

Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.

What is the price predicton of ONCO Stock?

Wall Street analysts forecast ONCO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ONCO is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Onconetix Inc (ONCO)'s revenue for the last quarter?

Onconetix Inc revenue for the last quarter amounts to 303.65K USD, decreased -25.37 % YoY.

What is Onconetix Inc (ONCO)'s earnings per share (EPS) for the last quarter?

Onconetix Inc. EPS for the last quarter amounts to -6.25 USD, decreased -97.49 % YoY.

What changes have occurred in the market's expectations for Onconetix Inc (ONCO)'s fundamentals?

The market is revising No Change the revenue expectations for ONCO for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -58.74%.

How many employees does Onconetix Inc (ONCO). have?

Onconetix Inc (ONCO) has 5 emplpoyees as of January 09 2026.

What is Onconetix Inc (ONCO) market cap?

Today ONCO has the market capitalization of 2.68M USD.